Pfizer Inc.'s Xalkori "Not Good Value for Money", Says National Institute for Clinical Excellence (NICE)
Published: Sep 25, 2013
Pfizer's lung cancer drug Xalkori should not be available on prescription under the National Health Service (NHS) because it does not provide value for money, says the National Institute for Health and Care Excellence (NICE). Final guidance on Xalokri (crizotinib) for previously treated ALK-positive advanced non-small-cell lung cancer (NSCLC) suggests the acquisition cost of the drug - around £4,689 per month - is too steep, even when Pfizer's discounted patient access scheme is taken into account. The final guidance is in line with NICE's draft appraisal issued in March, which concluded the drug would cost the NHS between £37,512 and £46,890 until disease progression, while a course after disease progression would be £51,579.
Help employers find you! Check out all the jobs and post your resume.